Current Perspectives on Left Ventricular Geometry in Systemic Hypertension

Progress in Cardiovascular Diseases

Volumn 59, Issue 3, 2016, Pages 235-246

  Oktay, Ahmet Afşin ^a   Lavie, Carl J ^a   Milani, Richard V ^a   Ventura, Hector O ^a   Gilliland, Yvonne E ^a   Shah, Sangeeta ^a   Cash, Michael E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anti hypertension therapy; Hypertension; Left ventricular geometry; Left ventricular hypertrophy; Remodeling

Indexed keywords

ALLOPURINOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; LOSARTAN; METOPROLOL; NIFEDIPINE; PLACEBO; TELMISARTAN; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DRUG MEGADOSE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR GEOMETRY; MORTALITY; NONHUMAN; OBESITY; PREVALENCE; PROGNOSIS; REVIEW; SLEEP DISORDERED BREATHING; WEIGHT LOSS PROGRAM; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; PROGNOSIS; VENTRICULAR REMODELING;

EID: 84992208856     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2016.09.001     Document Type: Review

References (98)

1. 1. Mozaffarian, D, Benjamin, EJ, Go, AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133:4 (2016), e38–360.
2. 2. Nadruz, W, Myocardial remodeling in hypertension. J Hum Hypertens 29 (2015), 1–6.
3. 3. Konstam, Ma, Kramer, DG, Patel, AR, Maron, MS, Udelson, JE, Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4 (2011), 98–108.
4. 4. Lavie, CJ, Patel, DA, Milani, RV, Ventura, HO, Shah, S, Gilliland, Y, Impact of echocardiographic left ventricular geometry on clinical prognosis. Prog Cardiovasc Dis 57 (2014), 3–9.
5. 5. Mancia, G, Fagard, R, Narkiewicz, K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
6. 6. Douglas, PS, Garcia, MJ, Haines, DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. J Am Coll Cardiol 57 (2011), 1126–1166.
7. 7. Marwick, TH, Gillebert, TC, Aurigemma, G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging 16 (2015), 577–605.
8. 8. Morbach, C, Lin, BA, Sugeng, L, Clinical application of three-dimensional echocardiography. Prog Cardiovasc Dis 57 (2014), 19–31.
9. 9. Lang, RM, Badano, LP, Mor-Avi, V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 16 (2015), 233–271.
10. 10. Armstrong, AC, Gidding, S, Gjesdal, O, Wu, C, Bluemke, DA, Lima, JAC, LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 8 (2012), 837–848.
11. 11. Coelho-Filho, OR, Mitchell, RN, Moreno, H, Kwong, R, Jerosch-Herold, M, Novel magnetic resonance imaging marker of diffuse myocardial fibrosis in hypertensive heart disease: the role of transcytolemmal water-exchange. J Cardiovasc Magn Reson, 14, 2012, O115.
12. 12. Coelho-Filho, OR, Shah, RV, Mitchell, R, et al. Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling. Circulation 128 (2013), 1225–1233.
13. 13. Milani, RV, Lavie, CJ, Mehra, MR, Ventura, HO, Kurtz, JD, Messerli, FH, Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol 97 (2006), 959–963.
14. 14. Lavie, CJ, Milani, RV, Ventura, HO, Messerli, FH, Left ventricular geometry and mortality in patients >70 Years of age with normal ejection fraction. Am J Cardiol 98 (2006), 1396–1399.
15. 15. Kuch, B, Muscholl, M, Luchner, A, et al. Gender specific differences in left ventricular adaptation to obesity and hypertension. J Hum Hypertens 12 (1998), 685–691.
16. 16. Cuspidi, C, Sala, C, Negri, F, Mancia, G, Morganti, A, Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 26 (2012), 343–349.
17. 17. Drazner, MH, Dries, DL, Peshock, RM, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas heart study. Hypertension 46 (2005), 124–129.
18. 18. Lee, M, Gardin, JM, Lynch, JC, et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the cardiovascular health study. Am Heart J 133 (1997), 36–43.
19. 19. Eguchi, K, Boden-Albala, B, Jin, Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 101 (2008), 1787–1791.
20. 20. de Simone, G, Palmieri, V, Bella, JN, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 20 (2002), 323–331.
21. 21. Artham, SM, Lavie, CJ, Milani, RV, Patel, DA, Verma, A, Ventura, HO, Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 52 (2009), 153–167.
22. 22. Lavie, CJ, Milani, RV, Ventura, HO, Cardenas, GA, Mehra, MR, Messerli, FH, Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol 100 (2007), 1460–1464.
23. 23. Santos, M, Shah, AM, Alterations in cardiac structure and function in hypertension. Curr Hypertens Rep 16 (2014), 1–18.
24. 24. Palmieri, V, Bella, JN, Arnett, DK, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: hypertension genetic epidemiology network (HyperGEN) study. Circulation 103 (2001), 102–107.
25. 25. Iwashima, Y, Horio, T, Kamide, K, et al. Additive interaction of metabolic syndrome and chronic kidney disease on cardiac hypertrophy, and risk of cardiovascular disease in hypertension. Am J Hypertens 23 (2010), 290–298.
26. 26. Chami, HA, Devereux, RB, Gottdiener, JS, et al. Left ventricular morphology and systolic function in sleep-disordered breathing the sleep heart health study. Circulation 117 (2008), 2599–2607.
27. 27. Roca, GQ, Redline, S, Claggett, B, et al. Sex-specific Association of Sleep Apnea Severity with Subclinical Myocardial Injury, ventricular hypertrophy, and heart failure risk in a community-dwelling cohort: the atherosclerosis risk in communities-sleep heart health study. Circulation 132 (2015), 1329–1337.
28. 28. Baggish, AL, Wang, F, Weiner, RB, et al. Training-specific changes in cardiac structure and function: a prospective and longitudinal assessment of competitive athletes. J Appl Physiol 104 (2008), 1121–1128.
29. 29. Hegde, SM, Solomon, SD, Influence of physical activity on hypertension and cardiac structure and function. Curr Hypertens Rep, 17, 2015, 77.
30. 30. Palatini, P, Visentin, P, Dorigatti, F, et al. Regular physical activity prevents development of left ventricular hypertrophy in hypertension. Eur Heart J 30 (2009), 225–232.
31. 31. Boman, K, Gerdts, E, Wachtell, K, et al. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. Eur J Cardiovasc Prev Rehabil 16 (2009), 242–248.
32. 32. Farquhar, WB, Edwards, DG, Jurkovitz, CT, Weintraub, WS, Dietary sodium and health: more than just blood pressure. J Am Coll Cardiol 65 (2015), 1042–1050.
33. 33. Jula, AM, Karanko, HM, Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation 89 (1994), 1023–1031.
34. 34. De arvao, A, Dawes, TJW, Shi, W, et al. Precursors of hypertensive heart phenotype develop in healthy adults a high-resolution 3D MRI study. JACC Cardiovasc Imaging 8 (2015), 1260–1269.
35. 35. Oktay, AA, Shah, SJ, Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. Curr Cardiol Rep, 16, 2014, 545.
36. 36. Rosen, BD, Edvardsen, T, Lai, S, et al. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the multi-ethnic study of atherosclerosis. Circulation 112 (2005), 984–991.
37. 37. Edvardsen, T, Rosen, BD, Pan, L, et al. Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging - the multi-ethnic study of atherosclerosis (MESA). Am Heart J 151 (2006), 109–114.
38. 38. Bliziotis, IA, Destounis, A, Stergiou, GS, Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens 30 (2012), 1289–1299.
39. 39. Veloudi, P, Blizzard, C, Head, G, Abhayaratna, W, Stowasser, M, Sharman, J, Blood pressure variability and prediction of target organ damage in patients with uncomplicated hypertension. Am J Hypertens 29 (2016), 1046–1054.
40. 40. Kollias, A, Lagou, S, Zeniodi, ME, Boubouchairopoulou, N, Stergiou, GS, Association of Central Versus Brachial Blood Pressure with Target-Organ Damage: systematic review and meta-analysis. Hypertension 67 (2016), 183–190.
41. 41. Essick, EE, Sam, F, Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens, 2011, 2011, 346985.
42. 42. Wei, S, Guo, A, Chen, B, et al. T-tubule remodeling during transition from hypertrophy to heart failure. Circ Res 107 (2010), 520–531.
43. 43. Shah, SJ, Aistrup, GL, Gupta, DK, et al. Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. Am J Physiol Heart Circ Physiol 306 (2014), H88–100.
44. 44. Berk, BC, Fujiwara, K, Lehoux, S, ECM remodeling in hypertensive heart disease. J Clin Invest 117:3 (2007), 568–575.
45. 45. LeGrice, IJ, Pope, AJ, Sands, GB, Whalley, G, Doughty, RN, Smaill, BH, Progression of myocardial remodeling and mechanical dysfunction in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol, 2012, 1353–1365.
46. 46. Rodrigues, JCL, Amadu, AM, Dastidar, AG, et al. Comprehensive characterisation of hypertensive heart disease left ventricular phenotypes. Heart, 2016 [Epub ahead of print].
47. 47. Higashikuni, Y, Tanaka, K, Kato, M, et al. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1 upregulation via nuclear factor B activation. J Am Heart Assoc, 2, 2013, e000267.
48. 48. Van Bilsen, M, Daniels, A, Brouwers, O, et al. Hypertension is a conditional factor for the development of cardiac hypertrophy in type 2 diabetic mice. PLoS One, 9(1), 2014, e85078.
49. 49. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
50. 50. Kannel, WB, Gordon, T, Offutt, D, Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 71 (1969), 89–105.
51. 51. Kannel, WB, Gordon, T, Castelli, WP, Margolis, JR, Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. Ann Intern Med 72 (1970), 813–822.
52. 52. Levy, D, Garrison, RJ, Savage, DD, Kannel, WB, Castelli, WP, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322 (1990), 1561–1566.
53. 53. Aro, AL, Reinier, K, Phan, D, et al. Left-ventricular geometry and risk of sudden cardiac arrest in patients with preserved or moderately reduced left-ventricular ejection fraction. Europace, 2016 [Epub ahead of print].
54. 54. Schillaci, G, Verdecchia, P, Porcellati, C, Cuccurullo, O, Cosco, C, Perticone, F, Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35 (2000), 580–586.
55. 55. Nunez, E, Arnett, DK, Benjamin, EJ, Oakes, JM, Liebson, PR, Skelton, TN, Comparison of the prognostic value of left ventricular hypertrophy in African-American men versus women. Am J Cardiol 94 (2004), 1383–1390.
56. 56. Rodriguez, CJ, Lin, F, Sacco, RL, et al. Prognostic implications of left ventricular mass among Hispanics: the northern Manhattan study. Hypertension 48 (2006), 87–92.
57. 57. Boner, G, Cooper, ME, McCarroll, K, et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 48 (2005), 1980–1987.
58. 58. Chatterjee, S, Bavishi, C, Sardar, P, et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol 114 (2014), 1049–1052.
59. 59. Khouri, MG, Peshock, RM, Ayers, CR, De Lemos, JA, Drazner, MH, A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry the Dallas heart study. Circ Cardiovasc Imaging 3 (2010), 164–171.
60. 60. Bang, CN, Gerdts, E, Aurigemma, GP, et al. Four-group classifcation of left ventricular hypertrophy based on ventricular concentricity and dilatation identifes a low-risk subset of eccentric hypertrophy in hypertensive patients. Circ Cardiovasc Imaging 7 (2014), 422–429.
61. 61. Garg, S, De Lemos, JA, Ayers, C, et al. Association of a 4-tiered classification of LV hypertrophy with adverse CV outcomes in the general population. JACC Cardiovasc Imaging 8 (2015), 1034–1041.
62. 62. Lieb, W, Gona, P, Larson, MG, et al. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging 7 (2014), 870–878.
63. 63. Rame, JE, Ramilo, M, Spencer, N, et al. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol 93 (2004), 234–237.
64. 64. Milani, RV, Drazner, MH, Lavie, CJ, Morin, DP, Ventura, HO, Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction. Am J Cardiol 108 (2011), 992–996.
65. 65. Neeland, IJ, Drazner, MH, Berry, JD, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol 61 (2013), 187–195.
66. 66. Group C, Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE echocardiography substudy. J Hypertens 29 (2011), 1439–1447.
67. 67. Barron, AJ, Hughes, AD, Sharp, A, et al. Long-term antihypertensive treatment fails to improve E/e??? Despite regression of left ventricular mass: an anglo-scandinavian cardiac outcomes trial substudy. Hypertension 63 (2014), 252–258.
68. 68. Wachtell, K, Bella, JN, Rokkedal, J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 105 (2002), 1071–1076.
69. 69. Wachtell, K, Palmieri, V, Olsen, MH, et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the losartan intervention for endpoint (LIFE) study. Circulation 106 (2002), 227–232.
70. 70. Zhang, K, Huang, F, Chen, J, et al. Independent influence of overweight and obesity on the regression of left ventricular hypertrophy in hypertensive patients: a meta-analysis. Medicine (Baltimore), 93, 2014, e130.
71. 71. Mancia, G, Zanchetti, A, Agebiti-Rosei, E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 95 (1997), 1464–1470.
72. 72. Schmieder, RE, Reversal of left ventricular hypertrophy in essential hypertension. JAMA 275 (1996), 1507–1513.
73. 73. Devereux, RB, Palmieri, V, Sharpe, N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluat. Circulation 104 (2001), 1248–1254.
74. 74. Devereux, RB, Dahlöf, B, Gerdts, E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation 110 (2004), 1456–1462.
75. 75. Galzerano, D, Tammaro, P, del Viscovo, L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 18 (2005), 1563–1569.
76. 76. Pitt, B, Reichek, N, Willenbrock, R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003), 1831–1838.
77. 77. Devereux, RB, Wachtell, K, Gerdts, E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292 (2004), 2350–2356.
78. 78. Pierdomenico, SD, Lapenna, D, Cuccurullo, F, Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 21 (2008), 464–470.
79. 79. Yasuno, S, Ueshima, K, Oba, K, et al. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the candesartan antihypertensive survival evaluation in Japan trial. J Hypertens 27 (2009), 1705–1712.
80. 80. Pierdomenico, SD, Cuccurullo, F, Risk Reduction after Regression of Echocardiographic Left Ventricular Hypertrophy in Hypertension: a Meta-Analysis. Am J Hypertens, 23, 2010, Nature Publishing Group, 876–881.
81. 81. Koren, MJ, Ulin, RJ, Koren, AT, Laragh, JH, Devereaux, RB, Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 12 (2002), 1021–1028.
82. 82. Okin, PM, Wachtell, K, Devereux, RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296 (2006), 1242–1248.
83. 83. Verdecchia, P, Angeli, F, Gattobigio, R, Sardone, M, Pede, S, Reboldi, GP, Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 19 (2006), 493–499.
84. 84. Okin, PM, Devereux, RB, Harris, KE, et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the losartan intervention for endpoint reduction in hypertension (LIFE. Hypertension 50 (2007), 984–990.
85. 85. Okin, PM, Devereux, RB, Harris, KE, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 147 (2007), 311–319.
86. 86. Messerli, FH, Cardiovascular effects of obesity and hypertension. Lancet 1 (1982), 1165–1168.
87. 87. MacMahon, SW, Wilcken, DE, Macdonald, GJ, The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 314 (1986), 334–339.
88. 88. Cuspidi, C, Rescaldani, M, Tadic, M, Sala, C, Grassi, G, Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis. Am J Hypertens 27 (2014), 146–156.
89. 89. Chen, G, McAlister, FA, Walker, RL, Hemmelgarn, BR, Campbell, NRC, Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 57 (2011), 891–897.
90. 90. Leung, M, Wong, VW, Hudson, M, Leung, DY, Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus. Circ Cardiovasc Imaging, 9, 2016, e003643.
91. 91. Gerdts, E, Okin, PM, Omvik, P, et al. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr Metab Cardiovasc Dis 19 (2009), 306–312.
92. 92. de Simone, G, Okin, PM, Gerdts, E, et al. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis 19 (2009), 634–640.
93. 93. Engberding, N, Spiekermann, S, Schaefer, A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 110 (2004), 2175–2179.
94. 94. Rekhraj, S, Gandy, SJ, Szwejkowski, BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 61 (2013), 926–932.
95. 95. Kao, MP, Ang, DS, Gandy, SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 22 (2011), 1382–1389.
96. 96. Szwejkowski, BR, Gandy, SJ, Rekhraj, S, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol 62 (2013), 2284–2293.
97. 97. George, J, Carr, E, Davies, J, Belch, JJF, Struthers, A, High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114 (2006), 2508–2516.
98. 98. Sawyer, DB, Siwik, DA, Xiao, L, Pimentel, DR, Singh, K, Colucci, WS, Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34 (2002), 379–388.